Psychedelics & Cannabis

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

A look at the association between cannabis use and schizophrenia, as well as the need for comprehensive public health policies and education.

What is new in research on psychedelics?

Do SSRIs impact on the antidepressant efficacy of psilocybin? Researchers performed an open-label trial of single-dose psilocybin in patients with TRD who were taking SSRIs.

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

What is the association between cannabis use disorders and schizophrenia? Researchers used a nationwide register-based cohort study to investigate these associations.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.

The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.

Explore the complex interaction of cannabis and psychosis, and the sociocultural stressors and resulting neurobehavioral symptoms.

In this CME article, learn more about the best practices for engaging patients in the informed consent process for psychedelic treatment and psychedelic-assisted psychotherapy.

From the brain-gut connection to neurocognitive and neuropsychiatric symptoms of long COVID, here are highlights from the week in Psychiatric Times.

A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.

Psychiatry: a field of medicine that is constantly evolving.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?

"If we ignore or do not successfully address these future risks, we may need more than luck to avoid these looming disasters."

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."

One psychiatrist recounts his experience with ketamine.

The second coming of psychedelics… what will the outcome be?